uMotif, a London, UK-based data capture company putting patients at the centre of clinical research, raised £2.4m in funding.
The round was led by Albion Capital, with participation from several angel investors.
The company intends to use the funds to scale up the team and build on the capabilities of the product, such as new language integration, and to expand into the Asia Pacific market.
Launched in 2012 by founders Bruce Hellman and Ben James, uMotif provides a cloud-based software platform giving the patient-facing technology required to capture real-world data (eCOA, ePRo, eConsent) for the next generation of clinical research initiatives – from early phase to post-marketing trials.
The technology is already in use by top pharma companies across Europe and North America, including AstraZeneca, Novartis and UCB across multiple therapeutic areas.
The platform is available on any device.
The company serves a client base in Europe and North America, which includes global pharma companies, academic medical centres and contract research organizations.